Articles tagged with Cancer Medication
Researchers at UCF developed a novel quantum dot probe that quickly detects and tracks cancer cells, speeding up the effectiveness of cancer treatments. This breakthrough technique uses electronic probes to emit a signal when attached to cancer cells, allowing for rapid imaging and measurement of treatment outcomes.
Researchers found that increasing EET levels promotes tumor growth and metastasis, even in cancers that rarely spread. Blocking EETs, however, could reduce tumor growth and metastasis, suggesting a potential new avenue for cancer treatment.
A recent study by University at Buffalo researcher Javier G. Blanco found a genetic link between childhood cancer treatment and heart problems. The research identified a specific gene variant that increases the risk of cardiotoxicity in patients treated with anthracyclines.
The Wistar Institute is developing a new drug to treat Epstein-Barr virus-related cancers by targeting the dormant EBV virus in patient cells. The project aims to create a viable drug candidate with potential to save countless lives globally.
Researchers at Queen's University identified a new mechanism that could explain immune resistance in cancer cells, suggesting nitroglycerin may boost the body's natural immune response to cancer. The discovery sheds light on the role of hypoxia and ADAM10 enzyme production in cancer cell resistance.
A study published in Medical Care explores ways to empower patients and transform cancer care systems to improve quality. Researchers propose new approaches, including accountable care and personal health records, to address racial disparities and wasteful overuse.
A new study is assessing the feasibility of identifying specific genetic markers in cancer patients' tumours to deliver more targeted treatments. The Lawson research team has developed a process for analyzing tumour DNA to provide a genetic profile report within three weeks, helping oncologists create tailored treatment plans.
A Phase II clinical trial of 75 AML patients treated with vorinostat and chemotherapy resulted in an 85% remission rate. Higher-risk patients showed a complete response rate of 100%, while those with -5/-7 cytogenetic alterations fared less well. The Phase III trial will compare this combination to standard-of-care frontline therapies.
A new drug, KPT-SINE, targets CRM1 protein to restore normal cell death pathways in cancer cells. This study provides proof-of-concept data for phase I clinical testing of KPT-SINE in patients with chronic lymphocytic leukemia (CLL) and related diseases.
A new study found a possible link between resistance to immunomodulator therapy and the presence of protein cereblon. Lowering cereblon levels allows IMiDs to work properly, suggesting that other mechanisms may play a role in drug resistance.
A new study by Northwestern University finds that joint pain is the most common reason for women to stop taking aromatase inhibitors, a common breast cancer medication. The research also highlights a gap between clinicians' reported side effects and women's actual experiences.
Researchers have developed ways to exploit the addictions of cancers to kill them without harming normal tissues. The study identified SUMOylation as a key biochemical process involved in coping with cancer cell stress, and inhibiting this enzyme may be a therapeutic strategy for myc-driven cancers.
Researchers at Mayo Clinic have found a combination of drugs that destroys 70% of chemotherapy-resistant ovarian cancer cells. The discovery highlights the role of molecule RhoB in tumor response and may help identify patients who benefit from this therapy.
Researchers at Loyola University Medical Center report positive results from a clinical trial of an experimental drug targeting tumor stem cells. The study found that the drug turned off key genes responsible for making cancer stem cells resistant to conventional drugs.
A new study found that taking two breast cancer medications together, anastrozole and fulvestrant, significantly extended the lives of women with metastatic breast cancer. Women who received the combination treatment lived over six months longer than those who took the drugs in sequence.
Androgen suppression therapy used to treat advanced prostate cancer may significantly increase the risk of heart disease and stroke, say specialists. This risk is often overlooked in standard management of the disease.
A new triple drug combination has been shown to increase tumour eradication in HER2-positive breast cancer by more than half, with 46% of patients achieving a pathological complete response. The treatment was well-tolerated and did not significantly increase side effects or cardiac risk compared to standard therapy.
A new meta-analysis of randomized studies involving 4,141 prostate cancer patients found no difference in cardiovascular deaths between those receiving androgen deprivation therapy (ADT) and those who didn't. The study suggests that ADT may not increase the risk of fatal heart attacks for men without a history of heart disease.
Research found that diabetes increases breast cancer risk by 37% in women diagnosed within four years of cancer development. Obesity after age 60 also significantly increases the risk, with a 55% increase in breast cancer cases compared to the general population. High and low blood lipids were also associated with different risks.
A research team discovered distinct gene patterns associated with early and late breast cancer recurrences, which could help predict patient outcomes and guide personalized therapy. The findings may enable oncologists to delay or prevent recurrences and reduce excessive treatment for patients who will not recur.
Researchers at Karolinska Institutet found that blood proteins EPO and PDGF-BB contribute to cancer tumour development and proliferation. The study suggests a potential therapeutic approach by targeting both proteins.
The American Society of Clinical Oncology (ASCO) has released its annual report on progress against cancer, showcasing the most significant developments in cancer research and policy. The report highlights advances in personalized treatment approaches, early detection, and new drug approvals for various cancers.
Researchers have developed a new tumor-targeting compound called PU-H71 that can reveal the complete set of aberrant signaling pathways driving cancers in individual patients. This breakthrough method uses the compound to identify abnormal proteins bound to heat shock protein 90, which are crucial for cancer cell growth and survival.
A new study by Michigan State University researchers found that metformin prevents tumors from growing in human cultures, providing biological evidence for its potential to reduce the risk of diabetes-associated cancers. The research suggests that metformin may be used as a preventive drug for individuals with Type-2 diabetes.
Researchers at the University of Texas Health Science Center have identified potent compounds in the bat plant that can selectively kill cancer cells. The taccalonolides stabilize microtubules in cancer cells without affecting healthy cells.
Scientists have identified a new class of drugs that target the proteasome in a unique way, leading to potential breakthroughs in cancer medication. The newly discovered hydroxyurea structures work more specifically than existing proteasome inhibitors, reducing severe adverse side effects.
A team of scientists at Sanford-Burnham Medical Research Institute has developed a new method for delivering cancer drugs directly to tumors, reducing side effects and increasing effectiveness. The technique uses a tumor-homing peptide that targets blood vessels feeding tumors, allowing the drug to be administered with minimal impact o...
Scientists identified a novel gene mutation causing glioblastoma, a common type of malignant brain tumor. Two existing drugs targeting this mutation effectively prolonged the survival of mice, offering new hope for patients.
A new device developed at the University of Colorado Cancer Center uses gold nanoparticles to detect lung cancer in exhaled breath, distinguishing between small-cell and non-small-cell lung cancer. The device has shown promising results in preliminary studies, with the potential to revolutionize lung cancer screening and diagnosis.
Researchers at Monash University discovered a gene that helps protect against squamous cell carcinoma, the most common form of skin cancer. The absence of this gene is a profound driver of SCC tumours, leading to unchecked cell growth and cancer.
Researchers found that silibinin from milk thistle prevents lung cancer growth by inhibiting COX2 and iNOS production. This natural compound may be as effective as current treatments for lung cancer, targeting promising therapeutic targets STAT1 and STAT3.
A large study found that 53% of male breast cancer patients experience tamoxifen-related side effects, leading to early discontinuation. The study suggests that these patients may be at increased risk of cancer recurrence.
Researchers at George Mason University have identified a key driver in inflammatory breast cancer, allowing for the development of new treatments. The study found that nearly all samples had high activation of the protein anaplastic lymphoma kinase (ALK), paving the way for targeted therapy.
Researchers at UC San Diego have identified a new class of drugs that can arrest division in virtually all tumor cells by altering the structure of the RAF enzyme. The discovery offers an effective alternative to current therapies and has shown promising results in tests on cancer cell lines, animal models, and human tissue biopsies.
A new study found that a novel histone deacetylase inhibitor drug, entinostat, can predict clinical benefit in breast cancer patients just days after treatment. The study showed that levels of protein lysine acetylation were related to clinical benefit, with patients who had elevated levels having a reduced risk of disease progression.
UCSF researchers have discovered the molecular basis for tamoxifen resistance and found a potential way to defeat it. They showed that cells can develop resistance through epigenetic modification, specifically by elevating expression of the 'survival' gene AKT.
Researchers have eliminated two possible causes of joint pain in women taking breast cancer medications: inflammatory arthritis and autoimmune disease. Despite finding no link between the medication and these conditions, doctors recommend continuing treatment to gain full benefits.
A combination epigenetic therapy has shown positive effects in a small clinical trial of late-stage lung cancer patients. The treatment increased median survival by two months and showed complete or near-complete responses in some patients. Researchers believe the therapy may reprogram gene expression to prevent cancer growth.
Researchers developed a new anti-obesity medication that targets fat cells, reducing body weight and abdominal circumference in rhesus monkeys. The treatment showed promise in improving insulin resistance and reversing metabolic syndrome, potentially providing a non-surgical solution to obesity.
The Scott & White Cancer Research Institute has received a $3.5 million grant from the Cancer Prevention Research Institute of Texas to develop new cancer treatments. The funds will be used to upgrade facilities and support the production of promising drug candidates, enabling rapid transition from laboratory to clinical trials.
A multidisciplinary research program aims to study the origins and pathogenesis of Barrett's esophagus, focusing on chronic inflammation and bile acids. The team will develop preventive and therapeutic treatments targeting stem/progenitor cells.
Patients with high EGFR expression have a survival advantage when treated with cetuximab plus chemotherapy, living up to 12 months on average. In contrast, those with low EGFR expression show no difference in overall survival.
USC Associate Professor Ellis Meng is selected for the NSF's Innovation Corps award to develop and commercialize her tiny, implantable medication-delivery system. The system has a better volume efficiency, allowing it to be powered wirelessly and used in animal studies.
A collaborative research partnership between Institut Pasteur Korea and Sanofi aims to combat Hepatitis B by developing a high-throughput assay to screen chemical libraries for novel compounds. The goal is to identify inhibitors targeting specific steps in the viral life cycle, offering new insights into HBV mechanisms.
Researchers found that inhibiting Notch signalling converts triple-negative breast cancer cells into hormone-receptor positive cells, making them dependent on estrogen. This technique has potential for combination therapy, where a Notch inhibitor is used to make all cancer cells hormone-sensitive.
A new study creates a comprehensive library of 178 kinase inhibitors targeting 300 enzymes, including those critical for cancer and other diseases. This library will aid researchers in developing cancer drugs that block specific kinases while minimizing side effects.
A new therapy uses folate receptors as a front door to deliver chemotherapeutic agents directly to cancer cells, improving effectiveness while reducing side effects. The strategy has shown a 72% improvement in progression-free survival for women with the most folate receptor overexpression.
A new study reveals that mTOR plays a key role in the complex signaling process that helps cells know when to grow and when to sit tight. The research found that mTOR turns itself on in a positive feedback loop involving the destruction of DEPTOR, a protein that normally holds it off.
Researchers at Johns Hopkins Medicine have developed a new breast cancer therapy that delivers anticancer drugs directly into the breast ducts via the nipple. The treatment has shown no major side effects in human patients and has been effective in animal models, with some drugs even preventing tumors from forming.
Researchers at Salk Institute discover a protein that defends against cancer also plays a key role in steroids' anti-inflammatory action. Targeting this protein could lead to new drugs without steroid side effects. The study suggests some cancer patients may not need steroid treatment due to genetic mutations.
Researchers at Lund University have created a molecular image of a drug in human tissue using a special type of mass spectrometry. The technique allows for precise spatial distribution analysis, enabling the development of safer and more effective drug candidates.
A recent study identified a protein called estrogen-related receptor alpha (ERRα) that fuels the growth of aggressive breast tumors. Researchers found that targeting this protein with an experimental drug can inhibit tumor growth in cellular models, offering a potential new approach for treating estrogen-receptor negative cancers.
NextBio's web-based tools aid in assessing potential drug efficacy and adverse effects by analyzing publicly available genomic data, identifying correlations with gene expression changes and cancer profiles.
A recent survey found high levels of anxiety and job dissatisfaction among over 2000 medical school faculty in the US. To address this, researchers propose six strategies called 'the Nepenthe principles' to enhance professional development, inclusivity, and creativity, ultimately improving productivity.
A new system being developed by researchers at the University of Strathclyde could administer drugs to lung cancer patients more efficiently without harmful side effects. The approach involves delivering treatment via nebulisation, potentially leading to improved patient outcomes and reduced mortality rates.
Researchers found that a mushroom compound, verticillin A, improves the efficacy of cancer drugs like TRAIL and etoposide by sensitizing cancer cells to cell death. The compound works by upregulating a gene called BN1P3, which promotes cell death and makes cancer cells more responsive to TRAIL.
Popular herbal supplements like feverfew, ginger, and St. John's Wort can interact with prescription medicines, posing serious side effects when combined during and after surgery. Discontinuing use at least one to two weeks prior to surgery can help avoid adverse events.
A new study has found that zoledronic acid can prevent and treat bone loss in postmenopausal breast cancer patients taking aromatase inhibitors. The five-year study showed significant increases in bone density when the drug was administered upfront, but also found that initiating treatment even after bone loss developed was beneficial.
Researchers identified 694 compounds that showed some activity against brain cancer stem cells, including four lead compounds that most successfully inhibited the cells. The study aims to reveal the biology of these stem cells and potentially result in a new therapy for deadly brain cancers.
Researchers at Sanford-Burnham Medical Research Institute have identified a new component of the cellular machinery that senses dietary amino acids, which is essential for mTORC1 activation. This finding provides new information about mTORC1 and its role in cellular metabolism in both normal cells and cancer cells.